Background: Cyclosporine is a potent immunosuppressant with nephrotoxic effects. The decreased effective renal blood flow caused by vasoconstriction of afferent arterioles is now considered the main mechanism of cyclosporine-induced nephrotoxicity, it has been suggested that endothelin (ET) receptor antagonists might have beneficial effects against cyclosporine-induced vasoconstriction. We studied the acute effect of a nonpeptide selective ET-A receptor antagonist, S-0139, against cyclosporine-induced reduction of renal cortical blood flow (RCBF). Methods: Male Wistar rats were divided into 3 groups (10 rats each). Both cyclosporine and S-0139 were dissolved in normal saline solution and infused into the femoral vein. Group 1 received cyclosporine at a dose of 0.1 mg/kg per minute. Group 2 received cyclosporine at the same dose and S-0139 at 0.2 mg/kg per minute. Group 3 received the medium as a control. RCBF was measured every 30 minutes for 4 hours by the hydrogen gas clearance method under urethane anesthesia. Serum creatinine, serum potassium, plasma endothelin 1 (ET1) concentrations and plasma renin activity were then measured. Results: Group 1 showed a significant decrease in RCBF, while groups 2 and 3 showed no change. Serum creatinine and serum potassium were significantly higher in group 1 than in groups 2 and 3. Plasma ET1 levels were both significantly higher in groups 1 and 2 than in group 3. There were no significant differences among the 3 groups in plasma renin activity.
Cyclosporine is a potent immunosuppressant, but it has nephrotoxic side effects. 1 To elucidate the mechanism of cyclosporine-induced nephrotoxicity, we did experiments using mice and rats, and obtained evidence that cyclosporine reduces renal cortical blood flow (RCBF), 2 enlarges the renin granules in the juxtaglomerular cells, 3 and does not affect plasma renin activity. 4 From these findings, we hypothesized that the decrease in the effective renal blood flow caused by the vasoconstriction of the afferent arterioles would be the key mechanism of cyclosporine-induced nephrotoxicity.
Endothelin is an endothelium-derived vasoconstrictor peptide 5 consisting of 21 amino acids, and there are 3 kinds of isopeptides: ET1, ET2, and ET3. Among these, ET1 is secreted mainly from the endothelium and acts as a strong vasoconstrictor by modulating cytoplasmic calcium via an ET-A receptor located on the surface of the vascular smooth muscle. 6 Although there has been a paper reporting that endogenous endothelin had no effect on renin secretion, 7,s Takagi et al. report that ET1 inhibits renin release from the juxtaglomerular cells. 9 Therefore, we thought that ET1 would be a mediator of the cyclosporine-induced vasoconstriction, as Kon et al. also point out. 1~ Several reports have suggested that endothelin receptor antagonists have beneficial effects against cyclosporine induced vasoconstriction. 11-13 We investigated the short-term prevention of cyclosporine-induced RCBF reduction by a new, potent, nonpeptide-selective ET-A receptor antagonist, S-0139.14
MATERIALS AND METHODS
Ten-week-old male Wistar rats, weighing about 200 g, were used in this study. The animals had free access to standard chow and water, and were exposed to a 12/12-hour, light-dark cycle, under controlled ternperature (22~ and humidity (50%).
On the day of the experiment, the animals were anesthetized with an intraperitoneal injection of urethane at a dose of 1000 mg/kg body weight. The right femoral vein was exposed with a minimal (i.e., about 1 cm in length) incision. A 24G, intravenous cannula was inserted into the femoral vein and fixed with 4-0 silk sutures, and then connected to the line from the microinfusion pump. The wound was then closed with 4-0 silk sutures. Next, the abdomen was opened with a minimum (i.e., about 4 cm in length) median incision and the left kidney was carefully exposed. RCBF was then measured every 30 minutes by the hydrogen gas clearance method, m using an electrolytic flow meter (Model RBF 2; Biomedical Science, Ishikawa, Japan). Blood pressure was not monitored. Amonopolar, needleshaped electrode was inserted into the renal cortex to the depth of i mm at the lower pole of the left kidney, and a disk-shaped counter electrode was set just behind the left kidney. The abdominal cavity was then filled with an adequate volume of normal saline solution. The wound was covered with a 4-cm square of cotton cloth during the RCBF measurement to reduce unnecessary fluid loss.
The animals were divided into 3 groups. Each group consisted of 10 animals. Group 1 received cyclosporine at a dose of 0.1 mg/kg per minute. Group 2 received both cyclosporine 0.1 mg/kg per minute and S-0139 at a dose of 0.2 mg/kg per minute. Group 3 (the control group) received the infusion medium. The dose of S-0139 for this study was determine d by preliminary experiments using Wistar rats (2 animals for each dose level). We found that S-0139 could not prevent cyclosporine-induced RCBF reduction at doses of 0.02 and 0.1 mg/kg per minute, but could maintain RCBF at doses of 0.2 and 1.0 mg/kg per minute. Thus, 0.2 mg/kg per minute of S-0139 was chosen for this study.
Both cyclosporine and S-0139 were dissolved in normal saline solution containing an equivalent concentration of the cyclosporine vehicle (CremophorTM; BASF Aktiienngesellschaft, Ludwigshafen, Germany) and injected continuously into the femoral vein for 4 hours using a microinfusion pump. To compensate for fluid loss during the RCBF measurement, all solutions, with or without medication, were prepared as they were infused at a constant rate of 0.5 mL/h. The cyclosporine was purchased from Sandoz Pharmaceutical, Basle, Switzerland. The S-0139, 27-0-3 [2-(3-carboxy-acryloylamino)-5-hydroxy-phenyl]-acryloyloxy myricerone sodium salt was the gift of Shionogi, Osaka, Japan. After measurement of the RCBF for 4 hours, about 8 mL of whole blood was taken from the left femoral artery to estimate the concentrations of serum creatinine, serum potassium, whole blood cyclosporine, plasma ET1, and plasma renin activity.
Serum creatinine was measured by using the Creatinine Analyzer 2 (Beckman Instruments, Galway, Ireland). Serum potassium was measured using an electrolyte analyzer (SERA 230; Horiba, Kyoto, Japan). Whole blood concentration of cyclosporine was measured by the fluorescence-polarization immunoassay method using a TDX cyclosporine monoclonal whole blood kit and a TDX analyzer (Dainabot, Tokyo, Japan). Concentration of ET1 and plasma renin activity was measured by radioimmunoassay. The data were analyzed by one-way analysis of variance, followed by the Student's t test for differences between means.
RESULTS
All the rats were well anesthetized by urethane during the measurement of RCBF. Spontaneous respiration was regular and stable, and bleeding from the wounds was almost nil. Reliable data were therefore obtained. All data are summarized in Fig. 1 and Table 1 .
Group I showed a significant (P < 0.05) decrease in RCBF within 4 hours, while groups 2 and 3 showed no changes in RCBF. Comparing the RCBF values, between groups, significant differences were seen between group 1 and the rest (versus group 2, P < 0.01, and versus group 3, P < 0.01). Serum creatinine and serum potassium of group 1 were both significantly higher than those of group 2 (P < 0.01 and P < 0.05, respectively) and group 3 (P < 0.01 andP < 0.05, respectively). S-0139 did not affect the whole-blood cyclosporine level, and the values were almost the same between group 1 and group 2. Plasma ET1 levels of groups 1 and 2 were both significantly higher than that of group 3 (P < 0.05 and P < 0.05, respectively). S-0139 showed no apparent effect on plasma ET1 concentration. There were no significant differences in plasma renin activity.
DISCUSSION
Lanese and Conger showed that cyclosporine constricts the isolated rat afferent arterioles, and that the constriction is completely blocked by an ET-A receptor antagonist, BQ-123 prevents both a decrease in RCBF and an increase in serum creatinine caused by cyclosporine. This is further evidence that cyclosporine-induced nephrotoxicity is mediated by ET1. Our position is that cyclosporine affects not only renal hemodynamics, but also renal tubular function, because isometric vacuolar degeneration of the proximal tubular epithelial cells is often caused by excessive cyclosporine administrationJ The hyperpotassemia observed in group 1 is thought to be due to both cyclosporine-induced effective renal plasma flow reduction, and tubular dysfunction. But tubular dysfunction would be a secondary change caused by ischemia, for example, because hyperpotassemia was not observed in group 2. No significant differences were seen in plasma renin activity between the 3 groups. We think that this is because cyclosporine-induced ET1 inhibits renin release from the juxtaglomerular cells. Since renin release is blocked by ET 1, the cyclosporineinduced nephrotoxic effects on the renin-angiotensinaldosterone system should not be a concern.
Many other factors, such as nitric oxide, cytoplasmic calcium, and prostaglandins, have been nominated for the role of mediator ofcyclosporine-induced nephrotoxicity. However, ET1 has been reported to affect the production of nitric oxide, endotheliumderived relaxing factor, and prosta-cyclin, as well as the modulation of cytoplasmic calcium levels.6 Therefore, ET1 itself must be a key substance in producing cyclosporine-induced nephrotoxicity.
CONCLUSION
A new, selective ET-A receptor antagonist, S-0139, showed an acute preventive effect against cyclosporine-induced RCBF reduction, and against cyclosporine-induced increases in serum creatinine and serum potassium as well. This is additional evidence that ET1 plays an important role in cyclosporine-induced nephrotoxicity.
